DAX24.423 +1,3%Est505.646 +1,2%MSCI World4.331 +0,1%Top 10 Crypto16,46 +3,1%Nas22.844 +0,4%Bitcoin102.516 -0,3%Euro1,1716 ±-0,0%Öl64,57 +0,4%Gold3.853 -0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
DroneShield A2DMAA Rheinmetall 703000 NVIDIA 918422 RENK RENK73 Siemens Energy ENER6Y Tesla A1CX3T Novo Nordisk A3EU6F Plug Power A1JA81 Bayer BAY001 Alibaba A117ME HENSOLDT HAG000 Lufthansa 823212 BASF BASF11 Deutsche Telekom 555750 thyssenkrupp 750000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX fester erwartet - Rekordhoch weiter in Sicht -- Asiens Börsen uneins - Feiertag in China -- BMW steigert US-Absatz deutlich
Top News
Neue Konkurrenz für Tesla-Aktie? Mitgründer Tarpenning will mit TELO Trucks den Markt für E-Pickups aufmischen Neue Konkurrenz für Tesla-Aktie? Mitgründer Tarpenning will mit TELO Trucks den Markt für E-Pickups aufmischen
Aktien von NVIDIA, Apple & Co.: Warum die Rally an den US-Börsen noch bis Jahresende andauern dürfte Aktien von NVIDIA, Apple & Co.: Warum die Rally an den US-Börsen noch bis Jahresende andauern dürfte
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Günstig global investieren mit unserem neuen FINANZEN.NET MSCI WORLD ETF - nur 0,12 % TER. Jetzt informieren!

Insmed Aktie

Kaufen
Verkaufen
Insmed Aktien-Sparplan
130,00 EUR ±0,00 EUR ±0,00 %
BMN
151,25 USD -1,56 USD -1,02 %
nachbörslich
BTT
Insmed jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.26,55 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1JJA3

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS4576693075

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolINSM

Insmed Aktien News

DatumMeistgelesen
PR NewswireInsmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025
PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireBloomberg 500 (B500) Index Adds Sixteen Securities Following Semi-Annual Reconstitution
Wer­bungInsmed-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireInsmed To Present at September Investor Conferences
PR NewswireFDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
PR NewswireInsmed Reports Second-Quarter 2025 Financial Results and Provides Business Update
PR NewswireInsmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025
PR NewswireInsmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension
PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireInsmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference
PR NewswireBrensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study
PR NewswireInsmed Reports First-Quarter 2025 Financial Results and Provides Business Update
PR NewswireInsmed To Present at the BofA Securities 2025 Health Care Conference
PR NewswireNew England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
PR NewswireInsmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025
PR NewswireInsmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference
PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireInsmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis
PR NewswireInsmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update
PR NewswireInsmed To Present at March 2025 Investor Conferences
PR NewswireInsmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025
PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireFDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025
PR NewswireInsmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireInsmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireInsmed To Present at December 2024 Investor Conferences
PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireInsmed To Present at November 2024 Investor Conferences
PR NewswireInsmed Reports Third-Quarter 2024 Financial Results and Provides Business Update
PR NewswireInsmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List
PR NewswireInsmed Unites Across Communities Around the World During Third Annual Global Day of Good
PR NewswireInsmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024
PR NewswireNew Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results
PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireInsmed Reports Second-Quarter 2024 Financial Results and Provides Business Update
PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR NewswireInsmed to Host Second-Quarter 2024 Financial Results Conference Call on Thursday, August 8, 2024
PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed News

Insmed News: auf dieser Seite finden Sie alle Insmed News und Nachrichten zur Insmed Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Insmed News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Insmed News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.